PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance
FDA identified no Filing review issues
Read more at globenewswire.comPolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
Barchart·07/29/2026 07:30:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.